Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Masami Taniguchi, Yosuke Kamide, Yuto Nakamura, Kentaro Watai, Yuma Fukutomi, Kiyoshi Sekiya
No abstract text is available yet for this article.
2024: Arerugī, [Allergy]
#22
JOURNAL ARTICLE
Michael E Wechsler, Parameswaran Nair, Benjamin Terrier, Bastian Walz, Arnaud Bourdin, David R W Jayne, David J Jackson, Florence Roufosse, Lena Börjesson Sjö, Ying Fan, Maria Jison, Christopher McCrae, Sofia Necander, Anat Shavit, Claire Walton, Peter A Merkel
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks...
February 23, 2024: New England Journal of Medicine
#23
JOURNAL ARTICLE
Sara Beça, Marco A Alba, José Hernández-Rodríguez, Georgina Espígol-Frigolé, Sergio Prieto-González, María C Cid, Núria Baños, Gerard Espinosa
OBJECTIVES: To analyze pregnancy outcomes of patients with primary systemic vasculitis followed in a third-level referral center. METHODS: Retrospective cohort study of all pregnant women with systemic vasculitis followed between 2009 and 2022 at the High-Risk Pregnancy Clinic of the Department of Systemic Autoimmune Diseases of the Hospital Clínic, Barcelona. RESULTS: Twenty women with primary vasculitis were identified, with a total of 30 pregnancies...
February 14, 2024: Seminars in Arthritis and Rheumatism
#24
REVIEW
Gianluca Screm, Lucrezia Mondini, Paola Confalonieri, Francesco Salton, Liliana Trotta, Mariangela Barbieri, Marco Mari, Nicolò Reccardini, Rossana Della Porta, Metka Kodric, Giulia Bandini, Michael Hughes, Mattia Bellan, Selene Lerda, Marco Confalonieri, Barbara Ruaro
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), all of which are characterised by inflammation of small-medium-sized vessels. Progressive understanding of these diseases has allowed researchers and clinicians to start discussing nailfold video capillaroscopy (NVC) as a future tool for many applications in daily practice...
January 24, 2024: Diagnostics
#25
JOURNAL ARTICLE
Xiaohang Liu, Yangzhong Zhou, Jing Li, Tianchen Guo, Zhuoyao Lv, Dingding Zhang, Xiaojin Feng, Jingdai Zhang, Ligang Fang, Xinping Tian, Xiaofeng Zeng, Wei Chen
OBJECTIVES: Currently, cardiac involvement is used to describe all eosinophilic granulomatosis with polyangiitis (EGPA) cardiac problems. However, heterogeneity exists among them. We aimed to depict the disease spectrum of EGPA cardiac involvement and identify high-risk population. METHODS: We included EGPA patients hospitalized in our center from 2012 to 2023 and in public databases. Based on the cardiac enzymes, cardiac magnetic resonance imaging, and endomyocardial biopsy results, the patients were divided into 3 groups: eosinophilic myocarditis (EGPA-EM), chronic inflammatory cardiomyopathy (EGPA-ICM) and EGPA-Control...
February 9, 2024: Rheumatology
#26
JOURNAL ARTICLE
Jianling Tao, Sai Liu, Maria Montez-Rath, Vivek Charu, Glenn M Chertow
INTRODUCTION: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and its subtypes, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA), frequently present with acute kidney injury and can often lead to kidney failure, even with successful induction therapy. Few contemporary, nationally representative studies have described hospital complications of AAV. METHODS: Using data from the 2016-2020 National Inpatient Sample, a nationally representative database, we identified hospitalizations from adults with a new diagnosis of AAV (subtype or unspecified) and an inpatient kidney biopsy during the index hospitalization...
2024: Glomerular diseases
#27
JOURNAL ARTICLE
Giovanna Elisiana Carpagnano, Andrea Portacci, Santi Nolasco, Aikaterini Detoraki, Alessandro Vatrella, Cecilia Calabrese, Corrado Pelaia, Francesca Montagnolo, Giulia Scioscia, Giuseppe Valenti, Maria D'Amato, Maria Filomena Caiaffa, Massimo Triggiani, Nicola Scichilone, Claudia Crimi
INTRODUCTION: Clinical remission (CliR) achievement has been recognized as a new potential outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features could better identify patients undergoing clinical remission. In this study, we aim to address this issue, tracing a possible identikit of patients fulfilling remission criteria. METHODS: We enrolled 266 patients with severe eosinophilic asthma (SEA) treated with a 12-month course of anti-IL5/IL5 receptor (IL5r) monoclonal antibodies...
2024: Frontiers in Immunology
#28
JOURNAL ARTICLE
Fariba Abbasi, Ata Abbasi, Alireza Rostamzadeh, Seyede Zohre Banihashemi, Aliakbar Rajabi
Churg-Strauss syndrome (CSS), recently named eosinophilic granulomatosis with polyangiitis (EGPA), is a rare form of systemic vasculitis with extravascular granulomas occurring in patients with asthma and tissue eosinophilia. We represent a large left ventricular granuloma, confirmed by histopathologic evaluation, detected as a ventricular mass by echocardiography in a 45-year-old asthmatic male who was admitted for a cerebrovascular accident. Paraclinical and histopathologic findings confirmed the diagnosis of EGPA...
November 1, 2023: Archives of Iranian Medicine
#29
Yuto Motobayashi, Chiyako Oshikata, Yuka Kodama, Kosuke Terada, Yuga Yamashita, Ryo Nakadegawa, Hinako Masumitsu, Reeko Osada, Hirokazu Takayasu, Nami Masumoto, Saki Manabe, Takeshi Kaneko, Akira Shiraishi, Naomi Tsurikisawa
Treating ocular involvement in eosinophilic granulomatosis with polyangiitis (EGPA) can be challenging. We present the case of a 37-year-old woman with EGPA who had severe bilateral visual field defects. Laboratory results showed leukocytosis (17,500 WBC/μL, 25.8 % eosinophils), negative MPO-ANCA titer, and elevated PR3-ANCA level (33.2 IU/mL). Diffusion-weighted MRI revealed bilateral hyperintense occipital lesions, which were more prominent on the left. Her therapy initially included a steroid pulse, followed by daily prednisolone, but her visual field defects remained refractory...
2024: Respiratory Medicine Case Reports
#30
JOURNAL ARTICLE
Qian Han, Jie Li, Jing Wang, Liming Zhang, Jun Zhang
This study aimed to investigate the concordance rate between the 2022 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria and the 1990 criteria for eosinophilic granulomatosis with polyangiitis (EGPA) in Chinese patients. 68 patients were diagnosed with EGPA according to the 1990 ACR criteria in the Department of Respiratory and Critical Care Medicine, Beijing Chao-yang Hospital Department, from May 2005 to December 2022, and those patients were reclassified using the 2022 ACR/EULAR criteria for EGPA...
January 26, 2024: Medicine (Baltimore)
#31
MULTICENTER STUDY
Alessandra Bettiol, Maria Letizia Urban, Roberto Padoan, Matthieu Groh, Giuseppe Lopalco, Allyson Egan, Vincent Cottin, Paolo Fraticelli, Claudia Crimi, Stefano Del Giacco, Laura Losappio, Laura Moi, Francesco Cinetto, Marco Caminati, Pavel Novikov, Alvise Berti, Paolo Cameli, Pascal Cathébras, Angelo Coppola, Cécile-Audrey Durel, Marco Folci, Alberto Lo Gullo, Carlo Lombardi, Sara Monti, Paola Parronchi, Carlos Martinez Rivera, Roser Solans, Angelo Vacca, Georgina Espígol-Frigolé, Gabriella Guarnieri, Fulvia Chieco Bianchi, Maria Rita Marchi, Colas Tcherakian, Jean-Emmanuel Kahn, Florenzo Iannone, Vincenzo Venerito, Charlene Desaintjean, Gianluca Moroncini, Santi Nolasco, Giulia Anna Maria Luigia Costanzo, Jan Walter Schroeder, Camillo Ribi, Michelangelo Tesi, Elena Gelain, Irene Mattioli, Federica Bello, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi
BACKGROUND: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. METHODS: This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022...
December 2023: Lancet Rheumatology
#32
JOURNAL ARTICLE
N Kozak, A Stakhova
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Charg-Strauss syndrome or allergic granulomatous angiitis, is defined as a systemic vasculitis identified by the presence of allergic rhinitis and/or asthma, correlated with the presence of marked eosinophilia in the peripheral blood, eosinophilic infiltration of various organs with extensive areas of necrosis, eosinophilic, giant cell vasculitis of vessels of small and medium caliber, as well as perivascular and interstitial necrotizing granulomas...
November 2023: Georgian Medical News
#33
Neeladri Misra, Khalid Mahmood
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) refers to a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels. It can be classified into various clinical disease phenotypes: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and renal-limited AAV or serologic subtypes, which are myeloperoxidase (MPO)-AAV and proteinase 3 (PR3)-AAV. Renal involvement is a common manifestation in these types of vasculitis...
December 2023: Curēus
#34
Ryu Sekiya, Tomoyuki Soma, Kazuyuki Nakagome, Makoto Nagata
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis accompanied by granulomas and eosinophilic inflammation, exhibiting marked peripheral blood eosinophiliaandasthma. Neuropathy is a difficult-to-treat common manifestation that frequently remains after achieving clinical remission with current therapy in a subpopulation of patients with EGPA with or without life-threatening organ involvement. Refractory neuropathy regularly reduces the quality of life and requires glucocorticoids (GCs) and/or immunosuppressants for a long time...
January 2024: Curēus
#35
JOURNAL ARTICLE
Alexandra M Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, Linda Green, Louise Thomson, Jodie Lam, Mariana Fernandes, Cris Roxas, Grainne d'Ancona, Andrew Hearn, Jessica Gates, Sangita Agarwal, Brian D Kent, Michelle Fernando, David P D'Cruz, Claire Hopkins, Tevfik F Ismail, Jaideep Dhariwal, David J Jackson
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multi-systemic disease characterised by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5-receptor monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown. OBJECTIVE: To assess the real-world effectiveness and clinical remission rates of anti-IL5R therapy in EGPA METHODS: We performed a retrospective cohort analysis of EGPA patients, who commenced treatment with benralizumab...
January 9, 2024: Journal of Allergy and Clinical Immunology in Practice
#36
JOURNAL ARTICLE
Chrong-Reen Wang, Hung-Wen Tsai, Chi-Chang Shieh
OBJECTIVE: Although sporadic case reports have demonstrated successful management of eosinophilic granulomatosis with polyangiitis (EGPA) by anti-IL-5 therapy, larger-scale monocentric studies for the efficacy of mepolizumab (MEP), an IL-5 monoclonal antibody, are still lacking in Taiwan. METHODS: Hospitalized EGPA patients aged at least 18 years were enrolled from November 1998 to October 2023, and analyzed for demographic, clinical, laboratory, medication and outcome data, focusing on the efficacy and safety of biologics use, particularly induction therapy with MEP...
January 9, 2024: Journal of the Formosan Medical Association
#37
JOURNAL ARTICLE
Marco Caminati, Claudio Micheletto, Francesca Norelli, Bianca Olivieri, Giancarlo Ottaviano, Roberto Padoan, Giorgio Piacentini, Michele Schiappoli, Gianenrico Senna, Francesco Menzella
INTRODUCTION: Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a significant advancement in the treatment of severe asthma and other Type 2 (T2) conditions, including nasal polyps, atopic dermatitis, and eosinophilic esophagitis. To date, Dupilumab has demonstrated optimal efficacy and safety profile. AREAS COVERED: The safety profile of dupilumab has been extensively studied, especially for its effects on blood eosinophil count...
January 10, 2024: Expert Opinion on Biological Therapy
#38
JOURNAL ARTICLE
David R W Jayne, Benjamin Terrier, Bernhard Hellmich, Paneez Khoury, Lee Baylis, Jane H Bentley, Jonathan Steinfeld, Steven W Yancey, Namhee Kwon, Michael E Wechsler, Praveen Akuthota
BACKGROUND: The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced oral corticosteroid (OCS) use compared with placebo in patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The present analysis investigated the impact of baseline characteristics on clinical outcomes and characterised the OCS-sparing effect of mepolizumab. METHODS: In a phase 3, randomised controlled trial for patients with EGPA (MIRRA), patients received standard of care plus mepolizumab 300 mg or placebo every 4 weeks for 52 weeks...
January 2024: ERJ Open Research
#39
JOURNAL ARTICLE
Alexandre Bourdin, Alexandre Matet, Helene Blin, Raymond Barnhill, Nathalie Cassoux
No abstract text is available yet for this article.
January 9, 2024: Ocular Immunology and Inflammation
#40
REVIEW
Samuel J Cler, M Allison Ogden, Nyssa Fox Farrell, Lauren T Roland, Colin E Diffie, John S Schneider
BACKGROUND: Chronic rhinosinusitis is a very common condition. Granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (eGPA) are systemic diseases which can contribute to the development of chronic rhinosinusitis in select patients. OBJECTIVE: Characterize the presenting features, diagnostic criteria, workup, and management of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis as they are encountered in otolaryngology clinics...
December 18, 2023: American Journal of Otolaryngology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
